AmyLaurenCummingsMD

PubMed

• 2 citations
  Consent document translation expense hinders inclusive clinical trial enrolment.
  Maria A Velez, Beth A Glenn, Maria Garcia-Jimenez, Amy L Cummings, Aaron Lisberg, Andrea Nañez, Yazeed Radwan, Jackson P Lind-Lebuffe, Paige M Brodrick, Debory Y Li, M...> ;Nature. 2023 Aug 1
• 8 citations
  Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.
  Jay M Lee, Ciaran J McNamee, Eric Toloza, Marcelo V Negrao, Jules Lin, Elaine Shum, Amy L Cummings, Mark G Kris, Boris Sepesi, Ilze Bara, Nino Kurtsikidze, Katja Schul...> ;Journal of Thoracic Oncology. 2023 Nov 1
• 1 citations
  Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib.
  Clayton P Smith, Michael Xiang, Stephanie M Yoon, Alan Lee, Dan Ruan, Jonathan W Goldman, Amy L Cummings, Aaron Lisberg, Edward B Garon, Drew Moghanaki> ;JTO Clinical and Research Reports. 2023 Mar 1
• 6 citations
  The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.
  David J Benjamin, Shuai Chen, Joanna B Eldredge, Shiruyeh Schokrpur, Debory Li, Zhikuan Quan, Jason W Chan, Amy L Cummings, Megan E Daly, Jonathan W Goldman, Matthew A...> ;JTO Clinical and Research Reports. 2022 Dec 1
• 4 citations
  Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
  Yinjie Gao, Michelle M Stein, Matthew Kase, Amy L Cummings, Ramit Bharanikumar, Denise Lau, Edward B Garon, Sandip P Patel> ;Cancer Immunology, Immunotherapy. 2023 Feb 1
• 6 citations
  Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
  Nanruoyi Zhou, Maria A. Velez, Benjamin Bachrach, Jaklin Gukasyan, Charlene M. Fares, Amy L. Cummings, Jackson P. Lind-Lebuffe, Wisdom O. Akingbemi, Debory Y. Li, Paig...> ;Lung Cancer. 2021 Aug 30
• 8 citations
  A phase Ib open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung ca...
  Edward B. Garon, Alexander I. Spira, Melissa Lynne Johnson, Lyudmila Bazhenova, Joseph Leach, Amy L. Cummings, Albert Candia, Robert L. Coffman, Mary J. Janatpour, Rob...> ;Clinical Cancer Research. 2021 Jun 9
• 17 citations
  Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
  Amy L. Cummings, Jaklin Gukasyan, Henry Lu, Tristan Grogan, Gemalene Sunga, Charlene M. Fares, Nicholas Hornstein, Jesse M. Zaretsky, James M. Carroll, Benjamin Bachra...> ;Nature Cancer. 2020 Nov 16
• 10 citations
  Targeted Therapy for Non-Small Cell Lung Cancer.
  Zorawar S. Noor, Amy L. Cummings, McKenna M. Johnson, Marshall L. Spiegel, Jonathan W. Goldman> ;Seminars in Respiratory and Critical Care Medicine. 2020 May 25
• 2 citations
  KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit.
  Amy L. Cummings, Edward B. Garon> ;Translational Lung Cancer Research. 2019 Dec 1
• 5 citations
  KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment.
  Amy L. Cummings, Kate M. Santoso, Jonathan W. Goldman> ;Translational Lung Cancer Research. 2019 Oct 1
• 49 citations
  Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer
  Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M. Zaretsky, Tristan Grogan, Hira Rizvi, Daniel K. Wells, James M. Carroll, Amy L. Cummings, John Madrigal, Benjamin P Jones, ...> ;Clinical Cancer Research. 2019 May 21
• 9 citations
  Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation
  Charlene M. Fares, Timothy Williamson, Matthew K. Theisen, Amy L. Cummings, James M. Carroll, Annette L. Stanton, Edward B. Garon, Krikor Bornazyan, Marshall L. Spiegel> ;JCO Clinical Cancer Informatics. 2018 Nov 16
• 21 citations
  Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
  Izak Faiena, Amy L. Cummings, Anna M Crosetti, Allan J. Pantuck, Karim Chamie, Alexandra Drakaki> ;Drug Design, Development and Therapy. 2018 Jan 23
• 3 citations
  The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
  Amy L. Cummings, Edward B. Garon> ;Cancer Biology & Medicine. 2017 Nov 15
• 353 citations
  A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
  Aaron Lisberg, Amy L. Cummings, Jonathan W. Goldman, Krikor Bornazyan, Nicholas Dean Reese, T. Wang, P. Coluzzi, Blanca A. Ledezma, Melody A. Mendenhall, Jaime Hunt, B...> ;Journal of Thoracic Oncology. 2017 Nov 1
• 8 citations
  Thyroid carcinoma metastases to axillary lymph nodes: report of two rare cases of papillary and medullary thyroid carcinoma and literature review.
  Amy L. Cummings, Melanie Goldfarb> ;Endocrine Practice. 2014 Mar 1
• Join now to see all

Lectures

• Electrostatic human leukocyte antigen-neoantigen interactions and durable benefit in non-small cell lung cancer patients treated with immunotherapy. 
  2019 ASCO Annual Meeting - 6/1/2019